These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 26655303

  • 1. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
    Wood M, Ates A, Andre VM, Michel A, Barnaby R, Gillard M.
    Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V, van Wieringen JP, Janssen HM, Fransen PM, Dierckx RA, Michel MC, Booij J, Elsinga PH.
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [Abstract] [Full Text] [Related]

  • 3. The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs.
    Rossi M, Fasciani I, Marampon F, Maggio R, Scarselli M.
    Mol Pharmacol; 2017 Jun; 91(6):586-594. PubMed ID: 28265019
    [Abstract] [Full Text] [Related]

  • 4. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC.
    Synapse; 2006 Dec 15; 60(8):599-608. PubMed ID: 17001660
    [Abstract] [Full Text] [Related]

  • 5. Discovery of D1 Dopamine Receptor Positive Allosteric Modulators: Characterization of Pharmacology and Identification of Residues that Regulate Species Selectivity.
    Lewis MA, Hunihan L, Watson J, Gentles RG, Hu S, Huang Y, Bronson J, Macor JE, Beno BR, Ferrante M, Hendricson A, Knox RJ, Molski TF, Kong Y, Cvijic ME, Rockwell KL, Weed MR, Cacace AM, Westphal RS, Alt A, Brown JM.
    J Pharmacol Exp Ther; 2015 Sep 15; 354(3):340-9. PubMed ID: 26109678
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T.
    J Med Chem; 2003 Aug 28; 46(18):3822-39. PubMed ID: 12930145
    [Abstract] [Full Text] [Related]

  • 7. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
    Gackenheimer SL, Schaus JM, Gehlert DR.
    J Pharmacol Exp Ther; 1995 Sep 28; 274(3):1558-65. PubMed ID: 7562534
    [Abstract] [Full Text] [Related]

  • 8. Quinpirole-induced 50 kHz ultrasonic vocalization in the rat: role of D2 and D3 dopamine receptors.
    Brudzynski SM, Komadoski M, St Pierre J.
    Behav Brain Res; 2012 Jan 15; 226(2):511-8. PubMed ID: 22015714
    [Abstract] [Full Text] [Related]

  • 9. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G, Silvano E, Rossi M, Millan MJ, Maggio R.
    Neuropharmacology; 2011 Jan 15; 60(2-3):439-45. PubMed ID: 21035472
    [Abstract] [Full Text] [Related]

  • 10. Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3 receptors.
    Fasciani I, Pietrantoni I, Rossi M, Mannoury la Cour C, Aloisi G, Marampon F, Scarselli M, Millan MJ, Maggio R.
    Eur J Pharmacol; 2018 Jan 15; 819():181-189. PubMed ID: 29223348
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
    Jantschak F, Brosda J, Franke RT, Fink H, Möller D, Hübner H, Gmeiner P, Pertz HH.
    J Pharmacol Exp Ther; 2013 Oct 15; 347(1):57-68. PubMed ID: 23863695
    [Abstract] [Full Text] [Related]

  • 12. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan 15; 280(1):83-97. PubMed ID: 8996185
    [Abstract] [Full Text] [Related]

  • 13. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A.
    J Pharmacol Exp Ther; 1995 Dec 15; 275(3):1239-46. PubMed ID: 8531087
    [Abstract] [Full Text] [Related]

  • 14. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
    Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH.
    Eur J Pharmacol; 2006 Dec 15; 552(1-3):36-45. PubMed ID: 17056032
    [Abstract] [Full Text] [Related]

  • 15. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors.
    McCormick PN, Wilson VS, Wilson AA, Remington GJ.
    Pharmacol Res; 2013 Apr 15; 70(1):66-71. PubMed ID: 23327779
    [Abstract] [Full Text] [Related]

  • 16. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R, Bardin L, Rodrigues M, Abrial E, Aliaga M, Newman-Tancredi A.
    Behav Pharmacol; 2009 Jul 15; 20(4):303-11. PubMed ID: 19584712
    [Abstract] [Full Text] [Related]

  • 17. Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors.
    Seeman P, Guan HC.
    Synapse; 2009 Aug 15; 63(8):705-9. PubMed ID: 19391149
    [Abstract] [Full Text] [Related]

  • 18. Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.
    Luderman KD, Conroy JL, Free RB, Southall N, Ferrer M, Sanchez-Soto M, Moritz AE, Willette BKA, Fyfe TJ, Jain P, Titus S, Hazelwood LA, Aubé J, Lane JR, Frankowski KJ, Sibley DR.
    Mol Pharmacol; 2018 Oct 15; 94(4):1197-1209. PubMed ID: 30068735
    [Abstract] [Full Text] [Related]

  • 19. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW.
    J Pharmacol Exp Ther; 1995 Dec 15; 275(3):1355-66. PubMed ID: 8531103
    [Abstract] [Full Text] [Related]

  • 20. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.
    Bonaventura J, Navarro G, Casadó-Anguera V, Azdad K, Rea W, Moreno E, Brugarolas M, Mallol J, Canela EI, Lluís C, Cortés A, Volkow ND, Schiffmann SN, Ferré S, Casadó V.
    Proc Natl Acad Sci U S A; 2015 Jul 07; 112(27):E3609-18. PubMed ID: 26100888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.